Home > Healthcare > Biotechnology > Bioservices > Mammalian Cell Fermentation Technology Market
Mammalian Cell Fermentation Technology Market Share
- Report ID: GMI6524
- Published Date: Aug 2023
- Report Format: PDF
Mammalian Cell Fermentation Technology Market Share
Major market players operating in the mammalian cell fermentation technology market include
- Thermo Fisher Scientific, Inc.
- Merck KGaA
- Danaher
- Lonza
- F. Hoffmann-La Roche Ltd
- Sartorius AG
- AstraZeneca
- Bristol-Myers Squibb
- Amgen
- Gilead Sciences
- Moderna, Inc.
- Regeneron Pharmaceuticals
These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
Frequently Asked Questions (FAQ) :
The global mammalian cell fermentation technology industry was valued at USD 38 billion in 2022 and is expected to reach USD 80.5 billion by 2032.
The monoclonal antibodies segment held a major market share of 41.9% in 2022 attributed to the pivotal role that antibodies play in therapeutic and diagnostic applications, leading to increased demand for efficient production methods.
North America mammalian cell fermentation technology industry accounted for a revenue of USD 18.2 billion in 2022 and is anticipated to record around 7.9% CAGR between 2023-2032 attributed to the thriving biopharmaceutical industry in the region.
Thermo Fisher Scientific, Inc., Merck KGaA, Danaher, Lonza, F. Hoffmann-La Roche Ltd, Sartorius AG, AstraZeneca, Bristol-Myers Squibb, Amgen, Gilead Sciences, Moderna, Inc., and Regeneron Pharmaceuticals among others.
Mammalian Cell Fermentation Technology Market Scope
×
Get a free sample of
Mammalian Cell Fermentation Technology Market
Inquiry Before Buying
Get special pricing options on this report
Request Sectional Data
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours
below